Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellistem Lupus
- Development stage
- Phase 2
- Lead developer
- Cells for Cells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Cellistem Lupus is an investigational allogeneic cell therapy composed of umbilical cord-derived mesenchymal stromal cells (MSCs). Developed by Cells for Cells, a spin-off of the Universidad de los Andes in Chile, in collaboration with the CORFO Regenero Consortium, it is designed to treat severe lupus nephritis, a critical renal manifestation of systemic lupus erythematosus (SLE). The therapy leverages the innate immunomodulatory and regenerative properties of MSCs, which can suppress overactive immune responses and promote tissue repair in the kidneys. Because these cells exhibit low immunogenicity, the treatment does not require genetic compatibility or HLA matching between the donor and the recipient. Cellistem Lupus is currently being evaluated in Phase II clinical trials to determine its efficacy and optimal dosing when added to standard-of-care immunosuppressive regimens.
- Brand names
- Cellistem Lupus
- Other names
- Umbilical cord-derived mesenchymal stromal cellsUC-MSCsCellistem-Lupus
Beyond the preview
Go deeper on Cellistem Lupus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellistem Lupus.